Drug Approval | May 25, 2026
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Revenue from operations climbed 13% to Rs. 886.87 crore
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
The decision marks a key step in the centralized EU review process
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Clearance marks major shift beyond chemotherapy
Subscribe To Our Newsletter & Stay Updated
